Nautilus Biotechnology

Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but slightly missed on profitability metrics as the company transitions from R&D to early commercialization. Revenue of $0.19M beat the $0.00M consensus due to the initial rollout of the Early Access Program and grant revenue. GAAP EPS of -$0.11 beat the -$0.14 expectation, primarily driven by disciplined R&D spending, which fell 8% YoY. However, gross margin was effectively negative due to early-stage service costs, missing the 50% technical consensus.